Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company announced. “We are delighted with the news of the preliminary results of the Phase III confirmatory study of our proprietary…
Read more
The European Commission has approved Lupkynis (voclosporin) to treat active lupus nephritis, a serious complication of systemic lupus erythematosus (SLE) that is characterized by kidney inflammation. The approval is valid in all European Union (EU) member states, as well as Iceland, Liechtenstein, Norway, and Northern Ireland. Lupkynis received a similar…
Columnist Kristiana Page introduces a three-part series about the challenges she’s faced in navigating chronic illness and relationships.
Lupus is an autoimmune inflammatory disease that can affect multiple systems in the body.
While the cause of lupus is often unknown, it is possibly due to a combination of genetics and the environment.
Lupus affects people in different ways, and symptoms vary among patients. Symptoms come and go during periods called flares.
